TABLE 2.

ELISA values for Lyme disease patient serum samples tested for IgG reactivity to VlsE and VlsE-derived peptides

PatientDiagnosisaELISA result (value) for diagnosisbImmunoblot resultcIgG ELISA result (value)b,d
IgMIgGCtN1N2N3C2C4C6VlsE
NA6LAP (6.90)NP P (1.602) N (0.146) P (0.754) N (0.107)N (0.119)N (0.097) P (1.353) P (0.275)
NA7ClinicalP (1.93)NPN (0.157)N (0.119)N (0.144)N (0.102)N (0.069)N (0.105) P (0.224) N (0.081)
NA8ClinicalP (4.41)PP P (2.057) P (0.803) N (0.097)N (0.160)N (0.103)N (0.106) P (1.031) P (0.319)
NA9EM, LAP (5.75)NPN (0.091)N (0.127)N (0.0890)N (0.087)N (0.152)N (0.144) P (0.293) N (0.090)
NA10LAP (7.48)NP P (1.026) N (0.207) P (2.105) N (0.168)N (0.241)N (0.154) P (2.263) P (1.450)
NA11ClinicalP (3.51)NP P (1.007) N (0.321) P (0.3) N (0.099)N (0.135)N (0.214) P (0.770) P (0.440)
NA12EM, clinicalP (4.33)PP P (1.800) N (0.079)N (0.076)N (0.117)N (0.096)N (0.093) P (0.899) P (0.639)
NA13LAP (8.45)PP P (2.429) P (0.433) P (1.268) P (1.495) P (0.270) P (0.271) P (1.428) P (1.605)
NA14LAP (5.49)NPN (0.174)N (0.305) P (0.208) N (0.175)N (0.239) P (0.258) P (0.454) P (0.192)
NA15EM, clinicalP (5.98)PP P (2.522) N (0.331) P (0.191) P (2.086) N (0.15)N (0.13) P (2.101) P (2.136)
NA16LAP (8.18)NP P (0.872) N (0.123) P (0.690) N (0.061)N (0.105)N (0.113) P (0.591) P (0.207)
NA17LAP (3.77)NPN (0.077)N (0.152)N (0.123)N (0.082)N (0.123)N (0.111) P (1.025) P (0.220)
NA20CSF C+P (5.82)PP P (2.241) P (0.602) P (0.802) P (0.275) N (0.118)N (0.116) P (1.458) P (0.853)
NA22CSF C+P (1.24)NPN (0.133)N (0.191)N (0.094)N (0.066)N (0.106)N (0.135) P (0.390) N (0.090)
NA18EM, C+P (2.58)NPN (0.062)N (0.233)N (0.071)N (0.064)N (0.103)N (0.088) P (0.684) N (0.123)
NA19EM, C+P (1.89)PPN (0.092)N (0.213)N (0.110)N (0.087) P (0.316) N (0.139) P (0.609) N (0.112)
NA21EM, C+P (3.87)PP P (1.661) E (0.420)N (0.153) P (0.225) N (0.185)N (0.171) P (1.464) P (0.195)
NA23EM, C+P (4.77)PPN (0.180) P (0.486) N (0.101)N (0.083)N (0.147)N (0.176) P (2.543) P (1.045)
NA24EM, C+P (3.91)PNN (0.306)N (0.256)N (0.132)N (0.127)N (0.190)N (0.158) P (1.993) P (0.160)
NA25EM, C+P (3.49)PNN (0.154)N (0.152)N (0.103)N (0.082)N (0.149)N (0.126) P (1.309) N (0.106)
NA26EM, C+P (2.80)PN P (0.935) P (1.073) P (0.507) P (0.483) P (0.485) P (0.435) P (1.025) N (0.150)
NA27EM, C+P (1.45)PNN (0.121) P (0.460) N (0.120)N (0.096) P (0.302) N (0.123) P (0.415) N (0.099)
NA28EM, C+P (2.27)PN P (0.665) N (0.281)N (0.135)N (0.109)N (0.178)N (0.168) P (1.054) N (0.137)
NA29EM, C+N (0.53)PNN (0.109)N (0.131)N (0.094)N (0.073)N (0.117)N (0.109) P (0.676) N (0.084)
NA30EM, C+P (1.75)NNN (0.129)N (0.186)N (0.107)N (0.075)N (0.113)N (0.104)N (0.202)N (0.106)
NA31EM, C+E (0.99)PNN (0.102)N (0.106)N (0.067)N (0.065)N (0.092)N (0.093)N (0.159)N (0.065)
NA32EM, C+E (0.95)PN P (0.766) N (0.289)N (0.140)N (0.125)N (0.143)N (0.142) P (0.425) N (0.117)
NA33EM, C+P (1.30)NNN (0.226) P (0.547) N (0.150)N (0.144)N (0.202)N (0.187)N (0.238)N (0.126)
NA34EM, C+P (1.58)PNN (0.195)N (0.133)N (0.074)N (0.082)N (0.113)N (0.143) P (1.153) N (0.110)
NA35EM, C+P (1.59)PNN (0.102)N (0.091)N (0.065)N (0.088)N (0.1)N (0.089) P (0.432) N (0.089)
NA36Rash, C+P (1.29)NNN (0.183)N (0.127)N (0.088)N (0.121)N (0.131)N (0.126)N (0.180)N (0.137)
NA37EM, C+N (0.18)NNN (0.114)N (0.233)N (0.072)N (0.075)N (0.124)N (0.135)N (0.159)N (0.073)
NA38EM, C+N (0.59)NNN (0.407)N (0.357)N (0.153)N (0.130)N (0.173)N (0.167) P (0.637) N (0.119)
NA39EM, C+N (0.05)NNN (0.157)N (0.098)N (0.077)N (0.081)N (0.115)N (0.116)N (0.173)N (0.087)
NA40EM, C+N (0.57)NNN (0.212)N (0.275)N (0.077)N (0.075)N (0.102)N (0.130) P (0.356) N (0.081)
NA41EM, C+N (0.58)NNN (0.167)N (0.186)N (0.111)N (0.129)N (0.194)N (0.183)N (0.318)N (0.133)
NA42EM, C+E (0.93)NNN (0.096)N (0.101)N (0.109)N (0.079)N (0.116)N (0.202)N (0.270)N (0.115)
  • a C+, culture positive; CSF, cerebrospinal fluid; LA, Lyme arthritis. Clinical diagnoses were made as described in Materials and Methods.

  • b P, positive; N, negative; E, equivocal (indeterminate). Bold values (positive) indicate samples with OD values greater than the mean plus 3 standard deviations of the negative control values.

  • c Lyme disease Marblot (MarDx).

  • d The values for control patients NA1 to NA5 were used to calculate the cutoff value (mean + 3 standard deviations). These were run in tandem on the ELISA plates with patient samples NA6 to NA31 or NA32 to NA42. The means + standard deviations (cutoff values) for these patients were as follows: for patients NA6 to NA31, 0.128 + 0.046 (0.265), 0.1842 + 0.079 (0.421), 0.096 + 0.024 (0.168), 0.116 + 0.025 (0.190), 0.150 + 0.039 (0.267), 0.126 + 0.032 (0.222), 0.115 + 0.036 (0.223), and 0.079 + 0.016 (0.127) for Ct, N1, N2, N3, C2, C4, C6, and VlsE, respectively; and for patients NA32 to NA42, 0.194 + 0.101 (0.497), 0.180 + 0.082 (0.425), 0.097 + 0.026 (0.173), 0.111 + 0.019 (0.168), 0.146 + 0.049 (0.292), 0.136 + 0.042 (0.260), 0.150 + 0.065 (0.344), and 0.085 + 0.025 (0.158) for Ct, N1, N2, N3, C2, C4, C6, and VlsE, respectively.